Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 28;8(53):90916-90924.
doi: 10.18632/oncotarget.18701. eCollection 2017 Oct 31.

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens

Jianhong Chen  1 , Xiaxia Zhang  1 , Hao Luo  1 , Chihong Wu  1 , Min Yu  1 , Dan Liu  1 , Hongli Xi  1 , Yihang Zhou  1 , Yaoyu An  1 , Xiaoyuan Xu  1
Affiliations

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens

Jianhong Chen et al. Oncotarget. .

Abstract

This study aimed to explore changes in hepatic and renal function indices in chronic hepatitis C (CHC) patients treated with direct-acting antivirals (DAAs). Forty-three CHC patients treated with sofosbuvir (SOF)-containing regimens were enrolled. At the end of treatment, the estimated glomerular filtration rate (eGFR) level was significantly decreased and the serum creatinine (Scr) and uric acid (UA) levels were significantly increased compared with baseline levels (eGFR: 86.7 ± 20.4 vs 80.5 ± 21.3, P01 = 0.005; Scr: 83.9 ± 19.1 vs 89.6 ± 21.1, P01 < 0.001; UA: 323.7± 86.2 vs 358.5 ± 93.2, P01 < 0.001); no significant improvements were observed at 24 w post-treatment (eGFR: 86.7 ± 20.4 vs 81.4 ± 18.6, P02 = 0.013; Scr: 83.6 ± 17.9 vs 87.9 ± 18.3, P02 = 0.014; UA: 320.8 ± 76.3 vs 349.3 ± 91.0, P02 = 0.004). When the patients were grouped by liver conditions, non-cirrhotic patients and cirrhotic patients had decreased eGFR levels and increased Scr levels at the end of treatment; at 24 w post-treatment, the eGFR and Scr levels were significantly improved in non-cirrhotic patients (88.4 ± 21.7 vs 83.8 ± 18.5, P02 = 0.142; 84.4 ± 20.4 vs 87.0 ± 16.9, P02 = 0.088), while no obvious improvements were observed in cirrhotic patients (84.3 ± 18.7 vs 78.1 ± 18.6, P02 = 0.002; 83.2 ± 17.7 vs 89.2 ± 20.6, P02 = 0.006). Clinical physicians should closely monitor renal function in patients treated with SOF-containing regimens, especially in cirrhotic patients.

Keywords: chronic hepatitis C; directly acting antivirals; nephrotoxicity; sofosbuvir.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that no conflicts of interest exists.

Figures

Figure 1
Figure 1. One decompensated cirrhotic patient with liver injury associated with treatment with DAAs
Figure 2
Figure 2. Changes in renal function indices among different observing points
(A) eGFR; (B) Scr; (C) UA; (D) BUN. T0: baseline; T1: end of treatment; T2: 24 w post-treatment. P01: statistical significance of the difference between T0 and T1; P02: statistical significance of the difference between T0 and T2.
Figure 3
Figure 3. Changes of eGFR and Scr levels in non-cirrhotic and cirrhotic patients
Changes of eGFR (A) and Scr (B) levels in non-cirrhotic patients; Changes of eGFR (C) and Scr (D) levels in cirrhotic patients; T0: baseline; T1: end of treatment; T2: 24 w post-treatment. P01: statistical significance of the difference between T0 and T1; P02: statistical significance of the difference between T0 and T2.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42. doi: 10.1002/hep.26141. - DOI - PubMed
    1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–57. doi: 10.1016/j.jhep.2014.07.027. - DOI - PubMed
    1. Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087–102. doi: 10.18632/oncotarget.7837. - DOI - PMC - PubMed
    1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38. doi: 10.1016/j.jhep.2006.05.013. - DOI - PubMed
    1. Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420–9. doi: 10.1053/j.gastro.2013.10.057. - DOI - PubMed